CanSino Biologics Inc. (688185.SH): The Phase I clinical trial of the freeze-dried b-type influenza streptococcus pneumoniae conjugate vaccine has started and the first subject has been enrolled.

CanSino Biologics Inc. (688185.SH) announced that their freeze-dried b-type influenza Haemophilus influenzae combination vaccine (hereinafter referred to as "Hib vaccine") has officially begun Phase I clinical trials recently and the first subject has been enrolled. The company's Hib vaccine is composed of purified Hib capsular polysaccharide covalently linked with tetanus toxin protein, in a freeze-dried form. It is expected to induce humoral immunity against Hib after vaccination, providing protection to the vaccinated individual. The Phase I clinical trial aims to evaluate the safety and immunogenicity of the freeze-dried b-type influenza Haemophilus influenzae combination vaccine in individuals aged 2 months and above, using a randomized, partially blinded, positive-controlled clinical trial design.